Introduction
Endoscopic endonasal skull base surgery (EESBS) has been associated with decreased overall morbidity and similar outcomes compared with open techniques. [1] [2] [3] [4] [5] However, EESBS can lead to a significant disruption in sinonasal anatomy and physiology, resulting in significant sinonasal morbidity, including nasal crusting, drainage, anosmia, and obstruction. 6, 7 While several quality of life (QOL) measures have been used for skull base surgery patients, [8] [9] [10] 
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A few studies have reported QOL outcomes for a wider range of tumor types and locations, both benign and malignant, with similar findings. For example, Derousseau et al, utilizing the SNOT-20 survey, found improvement in psychological and sleep outcomes, without improvement in rhinologic QOL, 1 and 2 years following EESBS for sinonasal malignancies. 16 McCoul et al demonstrated a transient deterioration in SNOT-22 scores in the immediate postoperative period, with significantly improved outcomes 6 and 12 months following EESBS for a variety of skull base lesions. 17 Glicksman et al reported improved SNOT-22 scores 3 months postoperatively following endoscopic resection for both benign and malignant lesions, with sustained improvement at 2 years. 18 Pant et al reported significantly improved outcomes at more than 6 months following EESBS compared with the first 3 months using the SNOT-22 for multiple endonasal endoscopic approaches. 19 Similarly, this study aims to evaluate sinonasal QOL outcomes using the SNOT-22 in patients undergoing EESBS at our institution, and to determine if extended beyond sella approaches (BSA) lead to worse QOL outcomes at 3 and 6 months compared with the simple SA.
Methods

Patient Selection
The current study was approved by the Institutional Review Board at Duke University Medical Center. The Duke Enterprise Data Unified Content Explorer was utilized to identify all patients who underwent EESBS between January 1, 2014, and April 30, 2017, at Duke University Hospital. EESBS was considered any surgery that involved an endonasal endoscopic approach for a lesion with gross involvement of the bone of the skull base with or without intracranial involvement. Purely mucosal lesions were not included. Electronic medical records were reviewed for clinical and operative details including age, gender, smoking status, tumor size, tumor type, approach, reconstruction method, and adjuvant radiation. Preoperative and postoperative (3 and 6 months) SNOT-22 scores were collected.
Surgical Technique
The endoscopic approaches were subdivided into a simple SA and BSA. All surgeries were performed by the surgeons at the Duke Skull Base Center, consisting of both otolaryngologists (D.W.J. and R.A.H.) and neurosurgeons (A.R.Z., P.E.F., and P.J.C.).
When both teams were involved, EESBS involved the twosurgeon, four-handed technique. While there was some variation in surgical technique depending on the surgeon, the SA generally consisted of a bilateral sphenoidotomy, removal of the intersinus septum and rostrum, a 1-cm posterior septectomy, and preservation of bilateral rescue flaps. Turbinate resection was left at the discretion of the surgeon. BSA consisted of any approach that included transplanum, transethmoid/cribriform, transclival, transpterygoid, and transmaxillary approaches to the skull base. Reconstructive technique was at the discretion of the surgical team and did not follow any specific algorithm. In general, only Gelfoam was used for cases in which no cerebrospinal fluid (CSF) leak was visualized. For cases with a CSF leak or significantly exposed neurovascular structures, any combination of abdominal fat, lumbar drainage, free mucosal graft, or pedicled nasoseptal flap (NSF) was used. A near-total resection was defined as more than 75% tumor resection and a partial resection was defined as less than 75% total resection of the tumor of interest.
Statistical Analysis
The SNOT-22 score was calculated as a sum of the 22 items on the questionnaire. The rhinologic domain of the SNOT-22 was calculated as the sum of the following six items: need to blow nose, sneezing, runny nose, thick nasal discharge, loss of smell/taste, and nasal blockage. If an incomplete SNOT-22 questionnaire had at least 50% of items completed, item-level missingness was imputed using mean of the completed items. The imputation method was utilized by Hopkins et al when missing data were encountered in their study to validate the SNOT-22 questionnaire, 11 and is consistent with studies utilizing other patient-based outcomes measures. 20 The primary outcomes were changes in SNOT-22 scores at 3 and 6 months postoperative compared with preoperative. Baseline characteristics were summarized using mean and standard deviation (SD) for continuous variables or frequency and percentage for categorical variables. A two-sample t-test was used to compare the mean difference between two groups for continuous variables, while chi-square or Fisher's exact test was used for categorical variables. Unadjusted and adjusted linear regression models were implemented to investigate the association between the types of endoscopic approach and changes in SNOT-22 scores. The covariates included in the adjusted regression model were age and tumor size as continuous variables and sex, smoking status, radiation history, and use of NSF as binary variables. Patients with missing values in any covariates were excluded from the regression analysis. Analysis was performed in R version 3.4.1 (Vienna, Austria). A p-value < 0.05 was considered significant.
Results
The initial search yielded 169 patients who underwent EESBS during the study period, of which 108 (63.9%) patients were in the SA group, while 61 (36.1%) were in the BSA group. Of the 61 BSA patients, 45 patients had a single extended endonasal approach performed (10 transpterygoid, 21 transethmoid/cribriform, 12 transclival, and 2 transplanum), while 14 patients had a combination of two approaches, and 2 patients had a combination of three approaches. The demographics of the two study groups are presented in ►Table 1. There was no significant difference between the two groups with regard to age, gender, and smoking status. However, tumor size (p < 0.0001), middle turbinate resection (p ¼ 0.02), and the rate of gross total resection were significantly higher (p ¼ 0.03) in the BSA group. Additionally, the need for adjuvant radiation treatment (p ¼ 0.001) was encountered more frequently in the BSA group. With regard to the reconstructive methods, the use of an abdominal fat graft was more common in the SA group (p < 0.001), but there was no significant difference in the use of NSFs, free mucosal grafts, or lumbar drains. Tumor pathologies are described in ►Table 2.
Three-Month Outcomes
Within the study cohort of 169 patients, preoperative and 3-month SNOT-22 scores were available for 84 (49.7%) patients. The mean SNOT-22 scores of the SA and BSA groups preoperatively were 19.7 (SD 16.5) and 30.1 (SD 20.2), respectively, and at 3 months were 21 (SD 16) and 24 (SD 19.7), respectively. ►Table 3 demonstrates the changes in total SNOT-22 score by approach 3 months after surgery. For these 84 patients, there was no significant difference in total SNOT-22 scores at 3 months compared with baseline, with a mean difference of À1.70 (95% confidence interval [CI] ¼ À 5.75, 2.32; p ¼ 0.40). An unadjusted regression model without covariates demonstrated that there was no significant association between the type of approach (SA vs. BSA) and change in SNOT-22 scores (estimate ¼ À 7.4; 95% CI ¼ À 15.4, 0.6; p ¼ 0.07). When the SA and BSA groups were compared in an adjusted regression model controlling for age, gender, smoking status, tumor size, radiation history, and NSF reconstruction as confounders, there was a significant decrease in SNOT-22 scores at the 3-month postoperative period for the BSA group (estimate ¼ À 9.9; 95% CI ¼ À 19.0, À0.8; p ¼ 0.04) (►Table 4).
As for the rhinologic domain, patients in the SA group had a greater degree of worsening of scores compared with the BSA group, but this difference was not statistically significant in both the unadjusted (estimate ¼ À 1.6; 95% CI ¼ À 4.4, 1.3; p ¼ 0.28) and adjusted (estimate ¼ À 0.2; 95% CI ¼ À 3.6, 3.2; p ¼ 0.90) regression models (►Tables 5 and 6).
Six-Month Outcomes
SNOT-22 scores were available for 49 (29.0%) patients at 6 months from surgery within the study cohort of 169 patients. The total SNOT-22 scores preoperatively for the 49 SA and BSA patients were 19.3 (SD 15.9) and 31.7 (SD 21.9), respectively, and at 6 months was 21 (SD 23.2) and 26.2 (SD 21.7), respectively (►Table 7). For the total study cohort, there was no significant difference in SNOT-22 scores at 6 months after surgery compared with baseline, with a mean As for the rhinologic domain, patients in the SA group had a greater degree of worsening of scores compared with the BSA group, but this difference was not statistically significant in both the unadjusted (estimate ¼ À 3.1; 95% CI ¼ À 7.6, 1.4; p ¼ 0.19) and adjusted (estimate ¼ À 2.7; 95% CI ¼ À 8.4, 3.1; p ¼ 0.37) regression models (►Tables 9 and 10). The rhinologic domain changes for the SA and BSA over the 6-month study period are demonstrated in ►Fig. 2.
Discussion
EESBS allows for a minimally invasive approach to the skull base that is associated with less postoperative morbidity and similar outcomes compared with traditional open approaches. The endoscope provides a wide view of the surgical field, which can be broadened with the use of angled telescopes. The extent of resection and oncologic outcomes has been shown not to be compromised. Additionally, patients incur shorter hospital stays and can frequently return to activities of daily life sooner. [1] [2] [3] [4] [5] Despite these benefits, EESBS can potentially cause significant sinonasal morbidity, especially with approaches that go beyond a simple transsellar approach.
The SNOT-22 is a validated and widely used instrument for patients with chronic rhinosinusitis. Due to the inherent similarities between endoscopic sinus and endoscopic skull base surgery, the SNOT-22 has been applied to EESBS. Using the SNOT-22 instrument, our study demonstrates that those undergoing EESBS do not experience significant changes to QOL scores at 3 and 6 months after surgery compared with preoperative scores. This finding is similar to prior reports that show normalization of scores occurring 3 to 12 months following surgery. For example, McCoul et al prospectively assessed SNOT-22 scores for 85 patients undergoing an endoscopic SA in addition to more extended approaches. 17 A univariate analysis of mean SNOT-22 scores was performed over a 1-year postoperative period, with significant worsening in SNOT-22 scores in the early postoperative period and significant improvements noted 1 year after surgery. Also similar to our study, tumor pathology and reconstructive methods did not affect QOL scores.
It is also notable that in our cohort, the patients with malignant lesions were overwhelmingly in the BSA group, since these lesions typically involved the anterior skull base. These patients were also more likely to have received adjuvant radiation. Despite this, we found that changes in SNOT-22 scores in the BSA group did not differ from those of the SA group. This is in contrast to a study by Pant et al, which tracked postoperative SNOT-22 scores in 51 patients undergoing a variety of endonasal approaches including transellar, transplanum, transpterygoid, transcribriform, and transclival. 19 The authors report that those undergoing transsellar approaches versus more extended approaches and those without NSF reconstruction were noted to have better SNOT-22 scores. Our findings are also in contrast to a study by Derousseau et al, which compared QOL outcomes using the SNOT-20 questionnaire in 72 patients undergoing endoscopic surgery for sinonasal malignancies. 16 At 2 years, the authors reported no significant improvements in the overall and rhinologic domain SNOT-20 scores for these patients.
One of the weaknesses of our study is that follow-up does not extend beyond 6 months, and it is possible that the BSA group, which had a higher rate of adjuvant radiation, could have worse QOL outcomes as late effects of radiation appear and recurrences are diagnosed. Additionally, our data show that use of NSF, which was more frequently used in the BSA group, did not result in worse QOL outcomes. This may be due to the small number of patients in each group undergoing NSF reconstruction, leading to inadequate power to detect a significant difference. Therefore, our results surrounding the NSF should be interpreted with caution.
There are some limitations to this study. As mentioned, almost half of the cohort did not have 3-month postoperative SNOT-22 data, and even fewer had 6-month data. One reason for this is that many patients were doing well at their 1 month postoperative visit and further follow-up was not necessary. It is possible that the BSA group, which had a higher rate of adjuvant radiation, could have worse QOL outcomes as late effects of radiation appear. Categorization of various extended endoscopic approaches into an allinclusive BSA group limits investigation of QOL outcomes that may be a unique approach. For example, it is expected that those undergoing a transcribriform approach will have greater olfactory dysfunction compared with those under-going transpterygoid approaches. However, the categorization of extended endoscopic approaches into a single subgroup was necessary due to the limited number of procedures performed per approach during the study period. 
Conclusion
Patients undergoing an extended endoscopic BSA did not experience diminished sinonasal QOL compared with baseline and compared with patients undergoing a simple SA. These results can be utilized to guide preoperative discussions and patient counseling. Larger studies are needed to evaluate QOL outcomes for specific approaches for specific tumors.
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